Public Consultation: Medicines and Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on a set of far-reaching proposals to improve and strengthen the UK clinical trials legislation to make the UK the best place to research and develop safe and innovative medicines.
Clinical trials are vitally important for achieving advances in medical treatment. There are a range of purposes why clinical trials may be conducted, for example to test whether a new treatment or combination of treatments is safe and effective, or to explore new ways to use existing medicines – as has been seen with the rapid introduction of new vaccines and therapeutics for COVID-19.
This eight-week consultation seeks your views on new proposals to improve the regulation of clinical trials in the best interests of patients. In line with the ambitions of the Life Sciences Vision these proposals for UK legislation seeks to make the UK the leading global centre for innovative research design and delivery, across all types of trials.
The consultation aims to promote patient and public involvement in clinical trials, improve the diversity of participants, streamline clinical trial approvals, enable innovation and enhance clinical trials transparency.
The consultation will run until 14th March 2022 More details can be found here.
